• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Novartis AG

    7/17/25 4:02:43 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    NOVARTIS AG

    (Name of Issuer)


    Ordinary Shares

    (Title of Class of Securities)


    66987V109

    (CUSIP Number)


    09/30/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    66987V109


    1Names of Reporting Persons

    UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    SWITZERLAND
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    126,084,217.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    139,602,467.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    139,602,467.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    HC

    Comment for Type of Reporting Person:  This filing is being submitted as of September 30, 2024. As of this reporting date, the combined positions of UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC, an aggregation unit within the Asset Management business division of UBS Group AG, were above the reportable threshold. The delay resulted from an inadvertent data issue related to UBS / Credit Suisse systems integration, which has now been identified and resolved.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    NOVARTIS AG
    (b)Address of issuer's principal executive offices:

    LICHTSTRASSE 35, BASEL, SWITZERLAND, CH 4056
    Item 2. 
    (a)Name of person filing:

    UBS Group AG
    (b)Address or principal business office or, if none, residence:

    UBS Group AG Bahnhofstrasse 45 PO Box CH-8021 Zurich, Switzerland
    (c)Citizenship:

    Switzerland
    (d)Title of class of securities:

    Ordinary Shares
    (e)CUSIP No.:

    66987V109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    139,602,467.00
    (b)Percent of class:

    6.37  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    126,084,217.00.

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    139,602,467.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Ownership of More than 5 Percent on Behalf of Another Person. Accounts managed on a discretionary basis by the UBS Asset Management division of UBS Group AG (UBS AM) have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities. To the best of our knowledge, no account holds more than 5 percent of the outstanding securities being reported in this filing.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Identification: UBS Asset Management (Americas) LLC. Classification: IA In addition to UBS Group AG, the following UBS Asset Management affiliates and subsidiaries are part of the UBS Asset Management division included in this filing: UBS AG, UBS Asset Management (Americas) LLC, UBS Asset Management (Australia) Ltd, UBS Asset Management (Deutschland) GmbH,UBS Asset Management (Europe) S.A., UBS Asset Management (Hong Kong) Ltd, UBS Asset Management (Japan) Ltd, UBS Asset Management (Singapore) Ltd, UBS Asset Management (UK) Limited, UBS Asset Management Life Limited, UBS Asset Management Switzerland AG, UBS Asset Management Trust Company, UBS Fund Management (Switzerland) AG, UBS Third Party Management Company S.A. , Credit Suisse Fund Management S.A., and MultiConcept Fund Management S.A.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    UBS AM is composed of wholly-owned subsidiaries and branches of UBS Group AG. UBS Group AG is reporting direct and indirect beneficial ownership of holdings. None of the reporting persons affirm the existence of a group within the meaning of Rule 13d 5(b)(1).
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
     
    Signature:/s/ Andrew Johnson
    Name/Title:Director
    Date:07/17/2025
    Get the next $NVS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVS

    DatePrice TargetRatingAnalyst
    8/8/2025$123.00Underweight → Equal-Weight
    Morgan Stanley
    2/13/2025Buy → Neutral
    UBS
    2/12/2025Underweight
    Morgan Stanley
    2/4/2025Hold → Buy
    Deutsche Bank
    12/4/2024Hold → Reduce
    HSBC Securities
    9/11/2024$135.00 → $130.00Buy → Neutral
    BofA Securities
    9/5/2024Buy → Neutral
    Goldman
    9/3/2024Buy → Hold
    Jefferies
    More analyst ratings

    $NVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Novartis AG upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Novartis AG from Underweight to Equal-Weight and set a new price target of $123.00

    8/8/25 7:57:50 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novartis AG downgraded by UBS

    UBS downgraded Novartis AG from Buy to Neutral

    2/13/25 8:48:14 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Novartis AG

    Morgan Stanley initiated coverage of Novartis AG with a rating of Underweight

    2/12/25 7:07:04 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 1, 2024 - FDA Roundup: November 1, 2024

    For Immediate Release: November 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “FDA Takes Exciting Steps Toward Establishing the Rare Disease Innovation Hub,” by Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER) and Peter Marks, M.D., Ph.D., director

    11/1/24 3:18:19 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVS
    SEC Filings

    View All

    SEC Form 6-K filed by Novartis AG

    6-K - NOVARTIS AG (0001114448) (Filer)

    8/11/25 4:34:13 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novartis AG

    6-K - NOVARTIS AG (0001114448) (Filer)

    7/17/25 4:15:04 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Novartis AG

    SCHEDULE 13G - NOVARTIS AG (0001114448) (Subject)

    7/17/25 4:02:43 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases

    Agreement to explore Argo's Phase 2 ANGPTL3 in a combination trial in dyslipidemia with an option to license second-generation molecules in the pipelineLicense to an additional Argo siRNA candidate currently in IND-enabling studiesArgo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity; Argo is also eligible to receive option payment, development, sales milestones and royalties on commercial salesSHANGHAI and BOSTON, Sept. 3, 2025 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma, the Company), a clinical-stage biotechnology company focused on developing next-generation siRNA therapeutic

    9/3/25 7:00:00 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease

    Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's disease1 Ianalumab has the potential to become the first and only targeted treatment approved for patients with Sjögren's diseaseIanalumab was well tolerated and demonstrated a favorable safety profile in Sjögren's disease1,2Novartis plans to present its data at an upcoming medical congress and submit to health authorities globallyEAST HANOVER, N.J., Aug. 11, 2025 /PRNewswire/ -- Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults wit

    8/11/25 1:20:00 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

    Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)14 out of 5 atherosclerotic cardiovascular disease (ASCVD) patients do not reach guideline-recommended LDL-C target, reinforcing urgent need for more aggressive LDL-C lowering2-5Twice-yearly Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainmentEAST HANOVER, N.J., July 31, 2025 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with d

    7/31/25 4:30:00 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVS
    Leadership Updates

    Live Leadership Updates

    View All

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $NVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Novartis AG

    SC 13D/A - NOVARTIS AG (0001114448) (Filed by)

    10/17/24 4:01:28 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVS
    Financials

    Live finance-specific insights

    View All

    PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

    - PTC to receive $1.0B in cash at closing -- PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones -- PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales -- Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study -- PTC will host a conference call on Dec. 2, 2024, at 8:30 am EST- WARREN, N.J., Dec. 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NY

    12/2/24 7:00:00 AM ET
    $NVS
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing

    JUST - EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULESJUST - EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF US$ 640 M, ADDITIONAL UNDISCLOSED PAYMENTS DEPENDENT ON PROGRESS INTO COMMERCIAL MANUFACTURING AND EXERCISING THE S.POD OPTIONTHE PARTNERSHIP ASPIRES TO DISRUPT THE BIOSIMILARS MARKET WITH AFFORDABLE AND ACCESSIBLE HIGHEST-QUALITY MEDICINES FOR PATIENTS ACROSS THE GLOBETHE PARTNERSHIP IS FOUNDED ON JUST - EVOTEC BIOLOGICS' AI-DRIVEN, FULLY INTEGRATED TECH PLATFORM AND CONTINUOUS MANUFACTURING COMBINED WITH SANDOZ' LEADING BIOSIMILARS PIPELINE AND CAP

    5/9/23 2:30:00 PM ET
    $EVO
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand Reports First Quarter 2023 Financial Results

    2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst

    5/4/23 4:01:00 PM ET
    $ANEB
    $LGND
    $NOVN
    Biotechnology: Pharmaceutical Preparations
    Health Care